Research advances in chronic hepatitis B with metabolic dysfunction-associated steatotic liver disease
- VernacularTitle:慢性乙型肝炎合并代谢相关脂肪性肝病的研究进展
- Author:
Ke YIN
1
;
Yuyun SONG
1
;
Feng LIU
1
Author Information
- Publication Type:Review
- Keywords: Hepatitis B， Chronic; Hepatitis B Virus; Fatty Liver
- From: Journal of Clinical Hepatology 2024;40(12):2499-2504
- CountryChina
- Language:Chinese
- Abstract: Chronic hepatitis B （CHB） and fatty liver disease are common chronic liver diseases in China. With the changes in lifestyle， the number of patients with CHB and metabolic dysfunction-associated steatotic liver disease （MASLD） is increasing year by year. Both CHB and MASLD may lead to adverse events such as liver cirrhosis and hepatocellular carcinoma （HCC）. The pathophysiological course of the liver during the coexistence of the two diseases may be different from the state of each disease alone， and consequently HBV replication may exist， affecting HBsAg seroclearance and antiviral therapy and increasing the risk of adverse events including hepatic fibrosis and HCC. It is clear that these problems will be of great significance to the monitoring， treatment， and prognosis of such patients. Therefore， this article briefly reviews the latest research advances in these problems.
